Pulse Biosciences: 86% of 43 patients met thyroid nodule six-month endpoint in PRECISE-BTN
Pulse Biosciences reported interim six-month results from its PRECISE-BTN study of the nPulse Vybrance system for symptomatic benign thyroid nodules, presented at the American Thyroid Association meeting. In the interim dataset of 43 patients, 86% achieved at least 50% nodule volume reduction at six months, and no serious adverse events were reported. The results are early, cover a subset of the study's enrolled patients, and do not include financial figures.
Key points
- 86% of the 43 evaluated patients achieved at least 50% nodule volume reduction at six months, the primary endpoint
- Median volume reduction was 72% at six months, with most reduction evident by the one-month visit
- ThyPRO-39 quality of life score improved 78% from baseline; 82% of patients with baseline neck pressure or fullness reported full resolution at six months
- No serious adverse events were reported; the company expects to report full six-month and 12-month data for all patients
The filing
Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.